Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786175 | PMC |
| http://dx.doi.org/10.4244/EIJ-E-23-00034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paclitaxel-Coated Balloon for the Management of In-Stent Coronary Restenosis: An Updated Meta-Analysis and Trial Sequential Analysis.
Catheter Cardiovasc Interv
January 2025
Department of Medicine, Federal University of Goiás, Goiânia, Brazil.
Background: Drug-coated balloons present a potentially advantageous therapeutic approach for managing coronary in-stent restenosis (ISR). However, the comparative benefits of paclitaxel-coated balloons (PCBs) over uncoated balloons (UCBs) remain unclear.
Aims: We conducted a systematic review and meta-analysis to evaluate and compare the clinical outcomes of patients treated with PCBs and UCBs.
Recurrent drug eluting stent, in-stent restenosis (DES-ISR): Epidemiology, pathophysiology & treatment.
Prog Cardiovasc Dis
January 2025
Division of Cardiovascular Medicine, Department of Medicine, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22909, United States of America. Electronic address:
Coronary artery in-stent restenosis (ISR) is driven by neointimal hyperplasia and neoatherosclerosis in previously placed stents. Drug eluting stents (DES) have been adopted as first line therapy for the initial episode of ISR. However, recurrent ISR has limited durable salvage options.
View Article and Find Full Text PDFDrug-Coated Balloons versus Drug-Eluting Stents for the Treatment of De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.
Rev Cardiovasc Med
December 2024
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 100069 Beijing, China.
Background: Because of the limitations in new-generation drug-eluting stents (DES), treatments advocating for non-stents with a drug-coated balloon (DCB) is now of great interest. Here, we conducted a meta-analysis to testify whether a DCB was more effective and safer than a DES in treating de novo coronary artery disease (CAD).
Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science to obtain high-quality trials comparing DCB with DES for the treatment of de novo CAD.
Recent Advances in the Treatment of Coronary In-Stent Restenosis.
Rev Cardiovasc Med
December 2024
Department of Cardiology, Bern University Hospital, Inselspital, CH-3010 Bern, Switzerland.
In-stent restenosis (ISR) remains the predominant cause of stent failure and the most common indication for repeat revascularization. Despite technological advances in stent design, ISR continues to pose significant challenges, contributing to increased morbidity and mortality among patients undergoing percutaneous coronary interventions. In the last decade, intravascular imaging has emerged as an important method for identifying the mechanisms behind ISR and guiding its treatment.
View Article and Find Full Text PDFSevere restenosis after stentless treatment with coronary intravascular lithotripsy for calcified nodule lesions: a serial observation with IVUS.
Oxf Med Case Reports
December 2024
Department of Cardiology, Pulmonology, Hypertension & Nephrolgy, Ehime University Graduate School of Medicine, Toon, Japan.
An 82-year-old woman with a history of myocardial infarction presented with worsening effort angina. Coronary angiography (CAG) revealed 75% stenosis in the proximal left anterior descending artery (LAD), with intravascular ultrasound (IVUS) identifying a severe calcified nodule near a previously implanted drug-eluting stent. The lesion was treated with intravascular lithotripsy (IVL) and a drug-coated balloon (DCB), avoiding left main crossover stenting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!